Mikhail Blagosklonny Contribution in Anti-aging and Cancer
Cancer is the primary issue in the medical field. It has continuously claimed many lives in the society. It has consequently attracted the attention of many scientists, physicians, researchers, and donors. The main aim of these individuals and organizations is coming up with cancer treatments different from therapies. One of the researchers who has used academic credentials and research skills into finding cancer treatment is Mikhail Blagosklonny. Mikhail is a scientist and a professor of oncology at Roswell Parker cancer institute. He holds an MD in internal medicine from First Pavlov state medical university of St. Petersburg. Mikhail graduated with a Ph.D. from the same university in Experimental Medicine and Cardiology. In 2002, he was made the associate professor of medicine at New York Medical College. He later served as the senior scientist in Ordway research institution. He joined Roswell Park Cancer Center in 2009. The massive experience he has gained over the years have made him become one of the excellent professors in oncology. His main research interest is based on underlying mechanisms of anti-aging drugs and cancer therapies that protect healthy cells from damage.
He currently works as the editor in chief of oncotarget and cell cycle; he is also the associate editor of cancer therapy and biology. The cells death and differentiation editorial board have come up with a hypothesis about TOR potential role in cancer and aging. He suggested the use of Rapamycin a popular drug used in the treatment of cancer. Mikhail is categorized as one of the passionate advocates of Rapamycin in longevity extension. His research ranges from cellular and molecular biology to clinical investigations. Mainly, he concentrates on tumor suppressors, drug resistance for healthy cells, ontogenesis, signal reduction, mitosis and anticancer therapeutics.
Mikhail Blagosklonny wrote the aging hyperfunction theory. He has also written about cyclotherapy and chemotherapeutic engineering. He is known for his substantial interest in oncology as he believes it is possible to cure cancer hence the suggestion of Rapamycin. More than three hundred research articles, chapters of books and reviews are written under his name. His interest in writing has made him an associate editor of the International Journal of Cancer, American Journal of Pathology and PLOS ONE. The main contributors to his success as one of the biggest oncology researchers in the world has been his hard work and commitment. He has indicated severally that his main drive into his field of work is the vision of seeing a disease free community. The population of Encourages is rising due to the discerning, punctual, constructive and multiple peer review. The reviews are helping oncology authors to increase the impact of their research.
Till recently, aging was believed to be a functional decline caused by the accumulation of random molecular damage. It was believed that it could not be prevented. A hyperfunction theory described aging as a continuation of growth caused by TOR. Hence, a model was created that predicts that rapamycin can be used in people to treat aging as well as prevent some diseases. With the right dosage, rapamycin can prevent aging and extend a healthy life span in human beings. Check Mikhail’s profile in LinkedIn